Oral bacteria in gut could play role in Parkinson’s disease development
Korean researchers have discovered that oral bacteria in the gut may contribute to Parkinson’s disease – highlighting a potential new target for treatment.
List view / Grid view
Korean researchers have discovered that oral bacteria in the gut may contribute to Parkinson’s disease – highlighting a potential new target for treatment.
A new study from UT Dallas and the Medical College of Wisconsin links chronic sickle cell disease pain to gut bacteria – identifying Akkermansia muciniphila as a potential target for new probiotic or microbiome-based therapies.
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
A new study, presented at the United European Gastroenterology, reveals how chronic stress disturbs the balance of gut microbiota and influences CRC progression.
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
Researchers find how antibiotic treatments influence the microbiota, providing new strategies for preventing antibiotic-induced damage.
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
Thousands of bile acids have been discovered, providing new insights into how microbes influence distant organ systems.
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
The interactions linking intestinal microbiota with the functionality of basally resident alveolar macrophages and severity of infection are revealed.
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.
A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.